Wednesday, September 27, 2017

=Cascadian Therapeutics (CASC) : tucatinib receives orphan drug designation

FDA granted orphan drug designation to tucatinib for the treatment of HER2-positive metastatic colorectal cancer

No comments:

Post a Comment